Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.28 +4.5%	$3.31	$2.63 ▼ $4.73	$628.05M	1.45	997,010 shs	1.25 million shs
CGC Canopy Growth	$1.03 +9.6%	$1.33	$0.77 ▼ $14.92	$163.37M	0.92	6.73 million shs	3.83 million shs
PRTA Prothena	$9.94 -2.7%	$13.27	$9.30 ▼ $25.42	$535.04M	0.07	495,780 shs	387,199 shs
REPL Replimune Group	$7.51 +2.2%	$11.34	$4.92 ▼ $17.00	$578.38M	1.26	867,695 shs	715,734 shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	0.00%	-2.79%	-4.85%	-6.27%	+7.90%
CGC Canopy Growth	0.00%	+2.17%	-14.55%	-60.67%	-87.95%
PRTA Prothena	0.00%	-5.89%	-25.62%	-22.16%	-54.05%
REPL Replimune Group	0.00%	-1.47%	-36.91%	-32.51%	+2.94%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	1.7117 of 5 stars	3.5	0.0	0.0	3.7	0.8	0.6
CGC Canopy Growth	2.1647 of 5 stars	2.5	2.0	0.0	2.8	0.0	1.3
PRTA Prothena	3.5307 of 5 stars	4.4	1.0	0.0	3.4	3.3	1.3
REPL Replimune Group	3.4376 of 5 stars	3.6	0.0	4.5	2.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	67.68% Upside
CGC Canopy Growth	1.00	Sell	$2.00	94.17% Upside
PRTA Prothena	2.75	Moderate Buy	$55.00	453.32% Upside
REPL Replimune Group	3.13	Buy	$19.43	158.70% Upside

Current Analyst Ratings Breakdown

Latest CGC, PRTA, REPL, and ABUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/28/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
2/26/2025	PRTA Prothena	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$94.00 ➝ $110.00
2/26/2025	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$16.00 ➝ $18.00
2/21/2025	PRTA Prothena	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$24.00 ➝ $20.00
2/21/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
2/21/2025	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$48.00 ➝ $48.00
2/21/2025	PRTA Prothena	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
2/13/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $22.00
2/7/2025	PRTA Prothena	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$58.00 ➝ $62.00
1/22/2025	REPL Replimune Group	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$18.00 ➝ $27.00
1/22/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $21.00

(Data available from 4/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	101.78	N/A	N/A	$0.63 per share	5.21
CGC Canopy Growth	$276.75M	0.59	N/A	N/A	$2.72 per share	0.38
PRTA Prothena	$135.16M	3.96	N/A	N/A	$10.46 per share	0.95
REPL Replimune Group	N/A	N/A	N/A	N/A	$6.26 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$72.85M	-$0.38	N/A	N/A	N/A	-1,137.65%	-68.18%	-51.55%	5/1/2025 (Estimated)
CGC Canopy Growth	-$487.23M	-$3.80	N/A	N/A	N/A	-156.98%	-56.52%	-24.18%	5/29/2025 (Estimated)
PRTA Prothena	-$147.03M	-$2.30	N/A	N/A	N/A	-90.50%	-22.67%	-19.68%	5/6/2025 (Estimated)
REPL Replimune Group	-$215.79M	-$3.07	N/A	N/A	N/A	N/A	-54.84%	-42.97%	5/15/2025 (Estimated)

Latest CGC, PRTA, REPL, and ABUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	N/A	N/A	N/A	$2.54 million	N/A
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.07	+$0.01	-$0.07	$2.20 million	$1.57 million
2/20/2025	Q4 2024	PRTA Prothena	-$1.02	-$1.08	-$0.06	-$1.08	$7.53 million	$2.12 million
2/12/2025	Q3 2025	REPL Replimune Group	-$0.70	-$0.79	-$0.09	-$0.79	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	7.02	7.02
CGC Canopy Growth	0.74	3.52	2.58
PRTA Prothena	N/A	11.52	11.52
REPL Replimune Group	0.14	11.43	11.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
CGC Canopy Growth	3.33%
PRTA Prothena	97.08%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	4.00%
CGC Canopy Growth	1.30%
PRTA Prothena	28.20%
REPL Replimune Group	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.48 million	181.91 million	Optionable
CGC Canopy Growth	3,150	158.61 million	153.39 million	Optionable
PRTA Prothena	130	53.83 million	38.64 million	Optionable
REPL Replimune Group	210	77.02 million	70.24 million	Optionable

CGC, PRTA, REPL, and ABUS Headlines

Recent News About These Companies

Vanguard Group Inc. Has $43.55 Million Holdings in Replimune Group, Inc. (NASDAQ:REPL)

April 14 at 3:21 AM | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from Analysts

April 13 at 3:13 AM | marketbeat.com

Wellington Management Group LLP Raises Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)

April 12 at 4:22 AM | marketbeat.com

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 11 at 4:01 PM | globenewswire.com

Replimune Group (NASDAQ:REPL) Shares Down 7.1% - Time to Sell?

April 11 at 12:34 PM | marketbeat.com

Why Replimune Group, Inc.’s (REPL) Stock Is Down 9.10%

April 10, 2025 | aaii.com

Replimune Group Inc.

April 9, 2025 | wsj.com

Trexquant Investment LP Sells 71,879 Shares of Replimune Group, Inc. (NASDAQ:REPL)

April 9, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Up 6.4% - What's Next?

April 4, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Trading Down 7.6% - What's Next?

April 1, 2025 | marketbeat.com

611,013 Shares in Replimune Group, Inc. (NASDAQ:REPL) Purchased by Artisan Partners Limited Partnership

March 30, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Swiss National Bank

March 30, 2025 | marketbeat.com

Charles Schwab Investment Management Inc. Has $6.16 Million Stake in Replimune Group, Inc. (NASDAQ:REPL)

March 25, 2025 | marketbeat.com

Rosalind Advisors Inc. Purchases New Position in Replimune Group, Inc. (NASDAQ:REPL)

March 23, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Shares Down 5.6% - What's Next?

March 22, 2025 | marketbeat.com

Victory Capital Management Inc. Purchases Shares of 44,880 Replimune Group, Inc. (NASDAQ:REPL)

March 22, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of "Buy" by Brokerages

March 17, 2025 | marketbeat.com

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 7, 2025 | globenewswire.com

Replimune price target raised to $18 from $16 at JPMorgan

February 26, 2025 | markets.businessinsider.com

Replimune price target raised to $22 from $21 at H.C. Wainwright

February 13, 2025 | markets.businessinsider.com

Navigating Uncertainty: Replimune Group’s Strategic Challenges Amid Clinical Trials and Global Risks

February 13, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
3 Defense Stocks Set to Benefit From Increased Military Spending
By Chris Markoch | March 20, 2025
View 3 Defense Stocks Set to Benefit From Increased Military Spending
3 Stocks Near 52-Week Lows With Strong Rebound Potential
By Gabriel Osorio-Mazilli | March 31, 2025
View 3 Stocks Near 52-Week Lows With Strong Rebound Potential
Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Delta, Walmart Cut Profit Targets: Could Start Domino Effect
By Thomas Hughes | April 10, 2025
View Delta, Walmart Cut Profit Targets: Could Start Domino Effect

CGC, PRTA, REPL, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.28 +0.14 (+4.46%)

As of 04:00 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Canopy Growth NASDAQ:CGC

$1.03 +0.09 (+9.57%)

As of 04:00 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Prothena NASDAQ:PRTA

$9.94 -0.28 (-2.74%)

As of 04:00 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Replimune Group NASDAQ:REPL

$7.51 +0.16 (+2.18%)

As of 04:00 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time